Zolmitriptan is a selective agonist for serotonin (5HT1 receptors). It relieves migraine by selective constriction of intracranial blood vessels, neuropeptide release inhibition and decreased transmission in the trigeminal pain pathway.
(in Tablet form)
The recommended dose of Zolmitriptan to treat a migraine attack is 2.5 mg. If symptoms persist or return within 24 hours, a second dose has been shown to be effective. If a second dose is required, it should not be taken within 2 hours of the initial dose. If a patient does not achieve satisfactory relief with 2.5mg doses, subsequent attacks can be treated with 5 mg doses of Zolmitriptan. In those patients who respond, significant efficacy is apparent within 1 hour of dosing,
Zolmitriptan is equally effective whenever the tablets are taken during a migraine attack; although it is advisable that Zolmitriptan tablets are taken as early as possible after the onset of migraine headache.
In the event of recurrent attacks, it is recommended that the total intake of Zolmitriptan in a 24-hour period should not exceed 15 mg.
Zolmitriptan is not indicated for prophylaxis of migraine.
Manufacturer: Square Pharmaceutical Ltd.